TT

Turn Therapeutics Inc.

TTRX·NASDAQ

$5.99

+1.1%
HealthcareBiotechnology

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$178.58M
EPS-0.2300
P/E Ratio-26.06
Earnings Date06/03/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal · Driver · Risk

Signal

Medium confidence

Valuation multiple is compressed (P/E -26.1).

Valuation inputs: P/E -26.1, earnings yield N/A, momentum +1.1%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE -68.2%, ROIC -94.4%).

Profitability stack: net margin 0.0%, ROE -68.2%, ROIC -94.4%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +61.5%, momentum +1.1%, net margin 0.0%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

t

Turn Therapeutics Inc. Market vs Earnings Trajectory

TTRX · NASDAQ

Loading price and EPS data...

TT

Turn Therapeutics Inc. Fair Value Envelope

TTRX · NASDAQ

Our analysis suggests that TTRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.9949, this represents a potential HIDDEN relative to our calculated worth for Turn Therapeutics Inc..

Intrinsic Value
Current Price: $5.9949
3Y+35.0%
5Y+35.0%
10Y+35.0%

No Revenue Data

TTRX has not reported any revenue values in the available annual periods.

3Y+39.0%
5Y+39.0%
10Y+39.0%
3Y+86.0%
5Y+86.0%
10Y+86.0%
3Y+91.0%
5Y+91.0%
10Y+91.0%
3Y+504.0%
5Y+504.0%
10Y+504.0%
TT

Turn Therapeutics Inc. Profit Bridge

TTRX · NASDAQ
Revenue0.00
Cost of Goods Sold (0.00)
Gross Profit0.00
Operating Expenses (5.86M)
Operating Income-5.86M
Interest Expense (0.00)
Other Income/Expense2.66M
Pretax Income-3.19M
Income Tax (0.00)
Net Income-3.19M
Net Income
-3.19M

Profitability Analysis

No Gross Profit Margin Data

TTRX has not reported any gross profit margin values in the available annual periods.

No Operating Profit Margin Data

TTRX has not reported any operating profit margin values in the available annual periods.

No Net Profit Margin Data

TTRX has not reported any net profit margin values in the available annual periods.

-68.15%
Return on Equity
-107%
3Y-97.0%
5Y-97.0%
10Y-97.0%
-26.26%
Return on Assets
-70%
3Y-77.0%
5Y-77.0%
10Y-77.0%
-94.42%
Return on Invested Capital
-27%
3Y-37.0%
5Y-37.0%
10Y-37.0%
T

Turn Therapeutics Inc. Cash Conversion Engine

TTRX · NASDAQ
Net Income-3.19M
Depreciation & Amortization52.75K
Stock-Based Compensation419.25K
Change in Working Capital2.37M
Others-2.21M
Capital Expenditures-152.99K
Free Cash Flow-2.72M

Cash Flow Quality Analysis

FCF Conversion Rate

85.0%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-6.0%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-85.9%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$2.37M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

t

Turn Therapeutics Inc. Funding & Solvency Profile

TTRX · NASDAQ
Cash & Cash Equivalents11.22M
Net Receivables0.00
Inventory0.00
Other Current Assets235.17K
Total Current Assets11 M
Property, Plant & Equipment67.57K
Goodwill & Intangible Assets919.95K
Long-Term Investments0.00
Other Non-Current Assets6.20M
Total Non-Current Assets6 M
Total Assets
18.64M

Financial Health Analysis

Current Ratio

2.23x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.05x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

6 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

61% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

t

Turn Therapeutics Inc. Street Expectations Map

TTRX · NASDAQ

No Target Data

No analyst price targets available for ttrx.

t

Turn Therapeutics Inc. Insider Positioning

TTRX · NASDAQ

During the last 12 months, there has been no insider trading activity reported for TTRX.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Neutral

No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.

Insider Participation

No Activity

No insider trading activity reported from any insiders in the past year.

No Dividend Yield Data

TTRX has not reported any dividend yield values in the available annual periods.

 

ttrx Dividend History

TTRX
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%